This is in keeping with the results of a study by Rotar et al. [21] on 2022 patients with either rheumatoid arthritis (RA), ankylosing spondylitis (AS), or PsA, which showed better persistence of golimumab compared to other TNFα blockers in biologic-experienced AS and PsA patients but not overall. Here, TNF is linked to ankylosing spondylitis.